Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AFM13 |
| Synonyms | |
| Therapy Description |
AFM13 is a tetravalent bispecific antibody targeting CD30 and CD16A, which recruits CD16A-expressing NK cells to CD30-expressing tumor cells, potentially inducing tumor cell killing and enhanced antitumor immune response (PMID: 26231785, PMID: 33986022). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AFM13 | AFM 13|AFM-13|Acimtamig | AFM13 is a tetravalent bispecific antibody targeting CD30 and CD16A, which recruits CD16A-expressing NK cells to CD30-expressing tumor cells, potentially inducing tumor cell killing and enhanced antitumor immune response (PMID: 26231785, PMID: 33986022). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03192202 | Phase Ib/II | AFM13 | AFM13 in Relapsed/Refractory Cutaneous Lymphomas | Completed | USA | 0 |
| NCT04101331 | Phase II | AFM13 | Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT) | Completed | USA | TUR | POL | ITA | FRA | ESP | DEU | AUS | 2 |
| NCT04074746 | Phase I | Cyclophosphamide + Fludarabine AFM13 | Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas | Completed | USA | 0 |